Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric study bill

This article was originally published in The Tan Sheet

Executive Summary

FDA's authority to require drug sponsors to conduct trials in children would expire at the same time as the pediatric exclusivity incentive program under a bill passed by the Senate July 23. Amendment to S 650 makes the bill applicable to all NDAs submitted "on or after April 1, 1999," the same date FDA's pediatric rule first took effect. Amendment also explains how deferral or waivers granted by FDA would apply retroactively. American Academy of Pediatrics supported amendment, but opposed the bill along with Democratic Sens. Christopher Dodd (Conn.), Hillary Clinton (N.Y.), Edward Kennedy (Mass.)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS095772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel